Telithromycin in Acute Exacerbation of Chronic Bronchitis - Full Text View

Purpose

Study objectives:

to document the clinical efficacy of telithromycin(800 mg per day for 5 days) at Test Of the Cure (TOC)visit (D12-D19), in acute exacerbation of chronic bronchitis.
to assess the long-term clinical efficacy of telithromycin by telephone at D25-D35 (V3)
to assess the safety of telithromycin

Condition	Intervention	Phase
Bronchitis, Chronic	Drug: Telithromycin	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Multicenter Non Comparative Phase IV Study on the Safety and Efficacy of Telithromycin 800 mg Per Day for 5 Days in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adults

Resource links provided by NLM:

MedlinePlus related topics: Acute Bronchitis Chronic Bronchitis

Drug Information available for: Telithromycin

U.S. FDA Resources

Further study details as provided by Sanofi:

Primary Outcome Measures:

Percentage of clinical success (cure + improvement) at TOC visit (D12-19),clinical success at TOC visit in at risk sub-populations, clinical success at follow up visit (D25-35), reinfection rates,discontinuation of treatment rates, compliance [ Time Frame: D12-D19 (efficacy assessment) and D25-D35 (telephone follow-up) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Safety assessment of telithromycin (Safety will be assessed on the basis of serious and non serious adverse events) [ Time Frame: At V3 ] [ Designated as safety issue: No ]


Enrollment:	54
Study Start Date:	January 2006
Study Completion Date:	January 2007
Primary Completion Date:	January 2007 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 telithromycin	Drug: Telithromycin one daily intake of 800 mg (i.e. 2 x 400 mg tablets) per os in a single intake with a meal for 5 days.

Eligibility


Ages Eligible for Study:	35 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Outpatients,
With a documented history of chronic bronchitis defined by one expectoration daily for at least three consecutive months over at least two consecutive years
Presenting with an evident acute exacerbation of their disease defined by the presence of at least two of Anthonisen's criteria:
- exacerbation of dyspnea,
- increase in the expectoration volume,
- increase in the expectoration purulence,

Exclusion Criteria:

Acute bronchitis,
Chronic obstructive pulmonary disease, those having FEV1 value <35% (FEV1: Forced Expiratory Volume in 1 second)
Suspected pneumonia or bronchial pneumonia,
Paroxysmal asthma or continuous dyspnea in asthma,
Cystic fibrosis,
Active tuberculosis,
Lung cancer or lung metastasis,
Severe bronchiectasia,
Acute respiratory decompensation,
Chronic respiratory insufficiency associated with resting hypoxemia,
Patients requiring hospitalization for parenteral antibiotic treatment
Patients with suspected or known bacterial infection other than study diseases, as well as associated systemic or intra-tracheal antibiotic treatment other than study treatment,
Participating in another clinical study with any product within 30 days before the inclusion of study
Known immunosuppression (AIDS and/or CD4+ lymphocytes < 200/mm3, neutropenia <1500/mm3, blood diseases or terminal stage cancer)
Cardiovasculary, neurologic or other severe diseases interfering with the compliance with study protocol or confusing with results.

Conditions associated with study medications:

Hypersensitivity against telithromycin , macrolides or any of the excipients,
Congenital long QT syndrome or family history of congenital long QT syndrome (this possibility should be excluded with normal ECG) or known acquired QT interval prolongation,
Treatment with CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, phenobarbital, St-John's-wort) within 2 weeks prior to the study inclusion
Possibility of treatment with ergot alkaloid derivatives, terfenadine, astemizole, pimozide, cisapride, simvastatin, athorvastatin or lovastatin during studies
Congenital galactosemia, lactase deficiency glucose or galactose malabsorption syndrome,
Pregnant or lactating women,
Women with childbearing potential (e.g. ovulating, pre-menopausal or not surgically sterilized) and do not employ any effective contraception method The patients may not participate to the study more than once. The patients who were treated with study drugs previously may not participate to the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00288223

Locations


Turkey
Sanofi-Aventis
Istanbul, Turkey

Sponsors and Collaborators

Sanofi

Investigators


Study Director:	Edibe Taylan	Sanofi

More Information


Responsible Party:	Medical Affairs Study Director, sanofi-aventis
ClinicalTrials.gov Identifier:	NCT00288223 History of Changes
Other Study ID Numbers:	HMR3647A_4022
Study First Received:	February 6, 2006
Last Updated:	December 8, 2009
Health Authority:	Turkey: Ministry of Health

Additional relevant MeSH terms:


Bronchitis Acute Disease Bronchitis, Chronic Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases	Respiratory Tract Infections Disease Attributes Pathologic Processes Pulmonary Disease, Chronic Obstructive Telithromycin Anti-Bacterial Agents Anti-Infective Agents

ClinicalTrials.gov processed this record on September 30, 2016